Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstract for Metastatic Uveal Melanoma at American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
27 avr. 2022 10h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10, a formulation of...
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunotherapy in Hematology
26 avr. 2022 07h30 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 26, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/688,319,...
Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board
14 avr. 2022 07h30 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 14, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Aru Narendran, MD, PhD to the Company’s Scientific Advisory Board. Dr. Narendran is a...
Provectus Biopharmaceuticals Announces Presentation of Multiple Protein Kinase Signaling Targets, including WNK1, for PV-10® Immunotherapy at American Association for Cancer Research (AACR) 2022 Annual Meeting
11 avr. 2022 07h30 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 11, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose...
Provectus Biopharmaceuticals Announces Synthesis of New Halogenated Xanthene Small Molecule
24 mars 2022 07h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 24, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has successfully developed and manufactured a second halogenated xanthene (HX), adding to...
Provectus Biopharmaceuticals Announces Oral Presentation of Updated Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference
16 mars 2022 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium)...
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Metastatic Uveal Melanoma Abstract for Oral Presentation at 2022 International Society of Ocular Oncology (ISOO) Congress
16 févr. 2022 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 for the treatment of...
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Systemic Administration Abstract at American Association for Cancer Research (AACR) Annual Meeting 2022
08 févr. 2022 05h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose...
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract for Oral Presentation at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference
01 févr. 2022 07h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 (rose bengal sodium),...
Provectus Biopharmaceuticals Provides Update on Research into PV-10® Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better
27 janv. 2022 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene...